TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05440981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTind device
Description: Cystoscopy will be performed to assess the anatomy of the bladder and prostate. The iTind device would be inserted under visual guidance into the bladder. The device will then be deployed and under visual guidance, it will be positioned at the prostatic lumen. After confirming the position of the device, cystoscopy will be withdrawn and the position will be finished.
Study: NCT04906954

Intervention type: OTHER
Group type: OTHER
Intervention: NMES
Description: Standardized strength program (75 Hz frequency, 40 cycles). The stimulation intensity will be increased up to the highest tolerated level in order to evoke strong muscle contractions.
Study: NCT00012740

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Casefinding and Referral System
Study: NCT05728970

Intervention type: DIAGNOSTIC_TEST
Intervention: LumiraDx SARS-CoV-2 Ag Ultra
Description: The LumiraDx SARS-CoV-2 Ag Ultra Test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from anterior nasal swab samples collected from symptomatic individuals within the first twelve days of symptom onset suspected of COVID-19 by their healthcare provider.

Intervention type: DIAGNOSTIC_TEST
Intervention: LumiraDx SARS-CoV-2 & Flu A/B
Description: The LumiraDx SARS-CoV-2 \& Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and/or Influenza B viral antigens from nasal swab samples.
Study: NCT06168318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation E
Description: Oral administration of VH4004280 Formulation E in fasted or fed conditions.
Study: NCT05006092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDOMIND
Description: CADe system for Polyp detection
Study: NCT06168318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation E
Description: Oral administration of VH4004280 Formulation E in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation E
Description: Oral administration of VH4004280 Formulation E in fasted or fed conditions.
Study: NCT06369649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coolsense and Buzzy
Description: Before the procedure, the independent observer, parent and child will be informed by the researcher about the method that will be used in the selected group and the scales that they will score. For children and parents in each group, a standard approach will be applied. Single blinding (participants) will be used in the research and the researchers will not have information about the other group. Cold application will be applied to children in group number one (Coolsense group). Coolsense, which does not contain any chemicals, provides cold application with the metal piece on its tip. In group number two (Buzzy group), vibration and cold application will be applied to the children. Buzzy is a handheld device with a bee-shaped motor that creates a small cold pad and vibration in the area in contact with the skin surface. Group number three (control group) will continue the standard procedure of the clinic and no different application or approach will be applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coolsense and Buzzy
Description: Before the procedure, the independent observer, parent and child will be informed by the researcher about the method that will be used in the selected group and the scales that they will score. For children and parents in each group, a standard approach will be applied. Single blinding (participants) will be used in the research and the researchers will not have information about the other group. Cold application will be applied to children in group number one (Coolsense group). Coolsense, which does not contain any chemicals, provides cold application with the metal piece on its tip. In group number two (Buzzy group), vibration and cold application will be applied to the children. Buzzy is a handheld device with a bee-shaped motor that creates a small cold pad and vibration in the area in contact with the skin surface. Group number three (control group) will continue the standard procedure of the clinic and no different application or approach will be applied.
Study: NCT06389916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Euclid orthokeratology MAX (current design)
Description: The current lens design

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Euclid orthokeratology MAX Phoenix (new design)
Description: The new lens design
Study: NCT06049732

Intervention type: DEVICE
Intervention: PainChek®
Description: Both PainChek® and the Abbey Pain Scale are observational pain assessment tools which have been designed to assist healthcare professionals and profession caregivers assess pain in people who cannot self-report their pain
Study: NCT06383442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-HIIT
Description: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: M-HIIT
Description: the medium-interval HIIT group (8 × 2 min Exercise /2 min Rest)
Study: NCT06674122

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral vitamin D supplementation of 800 IU/day
Description: Higher dose of enteral vitamin D supplementations (800 IU/day) are given for 28 days, and vitamin D status are examined before and after supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral vitamin D supplementation of 400 IU/day
Description: Standard recommended dose of enteral vitamin D supplementations (400 IU/day) are given for 28 days, and vitamin D status are examined before and after supplementation
Study: NCT06676514

Intervention type: DIETARY_SUPPLEMENT
Intervention: Butirrisan®
Description: Probiotic Clostridium butyricum CBM588®
Study: NCT06677320

Intervention type: OTHER
Intervention: Exercise
Description: Patients with rotator cuff disease will receive exercise treatment for two months.
Study: NCT05297422

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm surgey
Description: Microsurgery Clinic , KAT Hospital Athens

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm surgey
Description: Microsurgery Clinic , KAT Hospital Athens
Study: NCT05592093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Korean red ginseng capsule (marketed product in Korea)
Description: Korean red ginseng capsule (marketed product in Korea) KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Korean red ginseng capsule(placebo)
Description: KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group.~The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time.
Study: NCT05686148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration
Description: The device used for vibration application is produced to control pain and direct attention by providing 6000/min vibration. According to Melzack and Wall's Gate Control Theory, the application of local vibration reduces perceived pain by stimulating nerve fibers. Therefore, it should be ensured that the device is in full contact with the skin. The device can be used again by wiping with 70% alcohol. The device is placed 3 cm above the area to be injected. Vibration is applied to the area for 5 minutes before the procedure.
Study: NCT04916483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group cognitive stimulation therapy
Description: The experimental group will receive totally 7 weeks,14 sessions, twice a week, and 60 minute group cognitive stimulation therapy (GCST).
Study: NCT05297422

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm surgey
Description: Microsurgery Clinic , KAT Hospital Athens

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine
Study: NCT04916483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care
Description: The control group maintains the unit routine treatment.
Study: NCT05297422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine
Study: NCT06518512

Intervention type: DEVICE
Intervention: Automated Vision Assessment and Impairment Detection through Gaze Analysis (AVIGA) system
Description: AVIGA is an automated method and system for vision assessment of a subject. The method includes the following: determining a set of test patterns for the subject based on a preliminary assessment of an eye of the subject; displaying the set of test patterns sequentially to the subject; collecting data on the subject's gaze in response to each test pattern displayed; and correlating central vision function of the subjects to the collected gaze data.~Subjects perform the AVIGA test monocularly and pursue a pre-determined target moving in a customized waveform across the computer screen. The trail of the gaze points generated by the subject following the target is simultaneously recorded and stored.~1. Static Fixation Evaluation (SFE)~2. Static Perimetry Assessment (SPA)~3. Static Perimetry Sensitivity Assessment (SPSA)~4. Pursuit
Study: NCT04782128

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC28-E injection
Description: a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC28-E injection
Description: a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC28-E injection
Description: a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC28-E injection
Description: a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
Study: NCT05705570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60mg/Kg on day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m\^2 IV on days -5 to -3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0
Description: Level -1 (1 x 105 cells/kg)~Level 1 \[Starting dose\] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)
Study: NCT04801342

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conformal Whole Brain Radiotherapy with Unilateral Hippocampal Avoidance
Description: Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Unilateral Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conformal Whole Brain Radiotherapy with Bilateral Hippocampal Avoidance
Description: Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Bilateral Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Hydrochloride
Description: Start from day 1 of WBRT orally for 24 weeks and escalating doses over the first 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride
Description: Start from day 1 of WBRT orally for 24 weeks and escalating doses over the first 4 weeks
Study: NCT06676410

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV-specific antibodies
Description: Anti-HIV-1 specific antibody titers in plasma.
Study: NCT06400836

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate timing - carbohydrate intake before or after exercise
Description: The study aims to investigate how pre- or post evening exercise carbohydrate ingestion influences glucose metabolism and substrate oxidation (fat/CHO) during exercise and after exercise in athletes during the nocturnal period (21:00-06:00) and the morning after during an 120 minute oral glucose tolerance test (OGTT).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate timing - carbohydrate intake before or after exercise
Description: The study aims to investigate how pre- or post evening exercise carbohydrate ingestion influences glucose metabolism and substrate oxidation (fat/CHO) during exercise and after exercise in athletes during the nocturnal period (21:00-06:00) and the morning after during an 120 minute oral glucose tolerance test (OGTT).
Study: NCT06393595

Intervention type: DIAGNOSTIC_TEST
Intervention: surface enhanced Raman Spectroscopy
Description: Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried . The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope . The spectra were excited by laser module with a center wavelength of 785 nm. Each of the obtained spectra was a discrete set of 1700 parameters .~For skin Raman spectroscopy an experimental portable RS system was used, including a 785 nm diode laser , a portable commercially available Raman probe to filter the collected scattered radiation, and a portable spectrometer (QE65Pro, Ocean optics, Florida, USA). The scattered radiation was collected from the upper 1 to 2 mm thick skin layer. The Raman spectral range was 780-1000 nm with resolution of 0.2 nm. Each spectrum was recorded at an exposure time of 20 seconds with three-fold accumulation.
Study: NCT04551573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine daily
Description: In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine weekly
Description: In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
Study: NCT05605379

Intervention type: BIOLOGICAL
Intervention: Next Generation Sequencing (DNA and RNA)
Description: Targeted Next Generation Sequencing (DNA and RNA)

Intervention type: BIOLOGICAL
Intervention: Next Generation Sequencing (DNA and RNA)
Description: Targeted Next Generation Sequencing (DNA and RNA)
Study: NCT06676410

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV viral load (RNA)
Description: Performed on plasma.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV viral load (RNA)
Description: Performed on plasma.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Codivir® Training
Description: The participant is trained to self-inject Codivir®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dispensing Codivir®
Description: the participant receives Codivir®

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Codivir® Accounting
Description: The Codivir® used since the last visit is accounted for

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant medication
Description: Record of concomitant medications used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concomitant medication
Description: Record of concomitant medications used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adverse events
Description: Collection and recording of adverse events.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adverse events
Description: Collection and recording of adverse events.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretrovirals
Description: Tenofovir - inhibits HIV-1 reverse transcriptase activity by competing with the natural substrate, deoxyadenosine 5'-triphosphate and, upon incorporation into DNA, causes DNA chain termination.~* Lamivudine - potent selective inhibitor of HIV-1 and HIV-2 replication in vitro.~* Darunavir - prevents the formation of mature infective viral particles, indicated for the treatment of the human immunodeficiency virus (HIV), which causes AIDS.~* Ritonavir: antiretroviral protease inhibitor, widely used in combination with other protease inhibitors in the therapy and prevention of HIV infection, which causes the syndrome acquired immunodeficiency (AIDS).~* Single solid formulation (in 1 tablet) 1x/day with:~* Tenofovir (TDF) 300 mg~* Lamivudine (3TC) 300 mg~* Darunavir (DRV) 800 mg, 1x/day~* Ritonavir (RTV) 100 mg, 1x/day
Study: NCT06676423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lenzumestrocel
Description: 1.0 ⅹ 10\^6 cells/kg of Neuronata-R mixed with HTS-FRS suspension are administered twice in the cerebrospinal fluid at intervals of 26 days
Study: NCT05477953

Intervention type: DRUG
Intervention: Nifurtimox (BAYA2502)
Description: At least 1 dose of nifurtimox
Study: NCT06393595

Intervention type: DIAGNOSTIC_TEST
Intervention: surface enhanced Raman Spectroscopy
Description: Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried . The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope . The spectra were excited by laser module with a center wavelength of 785 nm. Each of the obtained spectra was a discrete set of 1700 parameters .~For skin Raman spectroscopy an experimental portable RS system was used, including a 785 nm diode laser , a portable commercially available Raman probe to filter the collected scattered radiation, and a portable spectrometer (QE65Pro, Ocean optics, Florida, USA). The scattered radiation was collected from the upper 1 to 2 mm thick skin layer. The Raman spectral range was 780-1000 nm with resolution of 0.2 nm. Each spectrum was recorded at an exposure time of 20 seconds with three-fold accumulation.

Intervention type: DIAGNOSTIC_TEST
Intervention: surface enhanced Raman Spectroscopy
Description: Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried . The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope . The spectra were excited by laser module with a center wavelength of 785 nm. Each of the obtained spectra was a discrete set of 1700 parameters .~For skin Raman spectroscopy an experimental portable RS system was used, including a 785 nm diode laser , a portable commercially available Raman probe to filter the collected scattered radiation, and a portable spectrometer (QE65Pro, Ocean optics, Florida, USA). The scattered radiation was collected from the upper 1 to 2 mm thick skin layer. The Raman spectral range was 780-1000 nm with resolution of 0.2 nm. Each spectrum was recorded at an exposure time of 20 seconds with three-fold accumulation.
Study: NCT05262192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: Nutrition education will be given to the patients in the experimental group.
Study: NCT05832216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab is a monoclonal globulin targeting the CD38 molecule of immune cells, which can eliminate antigen-presenting cells such as dendritic cells and macrophages, and indirectly reduce the production of autoantibodies. In addition, Daratumumab reduces autoantibody levels by targeting plasma cells, B lymphocytes and T lymphocytes.
Study: NCT06676423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: In the case of a subject who is not taking Riluzole at the time of screening (visit 1), Riluzole should be taken except when discontinued due to Adverse events. The dose can be changed within the authorization according to the medical expert's judgement
Study: NCT05256641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study: NCT05297864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: The starting dose will be 300 mg niraparib (or modified according patient weight and platelet count), taken orally once a day for each cycle of 28 days.
Study: NCT06629155

Intervention type: DIAGNOSTIC_TEST
Intervention: Infrared oculography
Description: Eye movements will be captured through infrared oculography and processed via in-house algorithms.
Study: NCT06085755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan will be administered 6.4mg/kg or 5.4mg/kg iv infusion q 3weeks as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib will be administered orally 20mg \~40mg once a day or three times a week(Monday, Wednesday, Friday \[MWF\]) or twice weekly (Monday, Thursday \[MT\]) for 3weeks as one cycle.
Study: NCT05875285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iontophoresis with methotrexate
Description: The methotrexate iontophoresis group the patient's hands are placed in direct contact with the conductive electrodes.~The patient will receive full explanation to the purpose of the treatment, the therapeutic and physiological benefits of this method of treatment. Before starting the treatment, all the previous measurements of each patient in this group is taken for a comparison.~Every patient will receive 12 sessions 3times/week every session consist of 30 minutes application of methotrexate iontophoresis using continuous direct current, the patient should feel mild tingling sensation (not painful), the polarity should be reversed halftime of treatment session, as the anodal current is more effective.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iontophoresis with coal tar ointement
Description: For coal tar ointement group the ointement is putted direct on the skin after describing the instruction and method of application and time of application and do alarm instead not to forget.